Literature DB >> 25453425

Steroids for acute respiratory distress syndrome?

Catherine L Hough1.   

Abstract

The development and severity of acute respiratory distress syndrome (ARDS) are closely related to dysregulated inflammation, and the duration of ARDS and eventual outcomes are related to persistent inflammation and abnormal fibroproliferation. Corticosteroids are potent modulators of inflammation and inhibitors of fibrosis that have been used since the first description of ARDS in attempts to improve outcomes. There is no evidence that corticosteroids prevent the development of ARDS among patients at risk. High-dose and short-course treatment with steroids does not improve the outcomes of patients with ARDS. Additional studies are needed to recommend treatment with steroids for ARDS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ARDS; Corticosteroids; Outcomes; Prevention; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25453425      PMCID: PMC4297198          DOI: 10.1016/j.ccm.2014.08.014

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  80 in total

Review 1.  The acute respiratory distress syndrome.

Authors:  L B Ware; M A Matthay
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

Review 2.  Molecular mechanisms of glucocorticoid action: what is important?

Authors:  R Newton
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

3.  Production of inflammatory cytokines in ventilator-induced lung injury: a reappraisal.

Authors:  J D Ricard; D Dreyfuss; G Saumon
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Pulmonary fibroproliferation and death in patients with late ARDS.

Authors:  G U Meduri
Journal:  Chest       Date:  1995-01       Impact factor: 9.410

5.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.

Authors:  Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

6.  Late steroid therapy in primary acute lung injury.

Authors:  T Varpula; V Pettilä; E Rintala; O Takkunen; V Valtonen
Journal:  Intensive Care Med       Date:  2000-05       Impact factor: 17.440

7.  Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome.

Authors:  David A Schoenfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2002-08       Impact factor: 7.598

8.  Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients.

Authors:  C Martin; L Papazian; M J Payan; P Saux; F Gouin
Journal:  Chest       Date:  1995-01       Impact factor: 9.410

9.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

10.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.

Authors:  L Cronin; D J Cook; J Carlet; D K Heyland; D King; M A Lansang; C J Fisher
Journal:  Crit Care Med       Date:  1995-08       Impact factor: 7.598

View more
  15 in total

1.  Use of corticosteroids in acute respiratory distress syndrome: Perspective from an Indian intensive care unit.

Authors:  Naveen G S Chandra; Saraschandra Vallabhajosyula; Barkur A Shastry; Shashaank Vallabhajosyula; Saarwaani Vallabhajosyula; Kavita Saravu
Journal:  Med J Armed Forces India       Date:  2016-12-16

2.  Successful management of prolonged venovenous extracorporeal membrane oxygenation in an octogenarian.

Authors:  Masami Takagaki; Hiroki Yamaguchi; Shinichi Mitsuyama; Tasuku Kadowaki; Takeshi Ando
Journal:  J Artif Organs       Date:  2017-10-06       Impact factor: 1.731

3.  The effectiveness of Corticosteroids on mortality in patients with acute respiratory distress syndrome or acute lung injury: a secondary analysis.

Authors:  Zhongheng Zhang; Lin Chen; Hongying Ni
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

4.  Acute Respiratory Distress Syndrome as an Organ Phenotype of Vascular Microthrombotic Disease: Based on Hemostatic Theory and Endothelial Molecular Pathogenesis.

Authors:  Jae C Chang
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

5.  Oleic acid-based nanosystems for mitigating acute respiratory distress syndrome in mice through neutrophil suppression: how the particulate size affects therapeutic efficiency.

Authors:  Huang-Ping Yu; Fu-Chao Liu; Ani Umoro; Zih-Chan Lin; Ahmed O Elzoghby; Tsong-Long Hwang; Jia-You Fang
Journal:  J Nanobiotechnology       Date:  2020-01-31       Impact factor: 10.435

6.  Management and Outcomes of Acute Respiratory Distress Syndrome Caused by Blastomycosis: A Retrospective Case Series.

Authors:  Ilan S Schwartz; John M Embil; Atul Sharma; Stephen Goulet; R Bruce Light
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

7.  Plasma Biomarker Analysis in Pediatric ARDS: Generating Future Framework from a Pilot Randomized Control Trial of Methylprednisolone: A Framework for Identifying Plasma Biomarkers Related to Clinical Outcomes in Pediatric ARDS.

Authors:  Dai Kimura; Jordy Saravia; Cynthia R Rovnaghi; Gianfranco Umberto Meduri; Andreas Schwingshackl; Stephania A Cormier; Kanwaljeet J Anand
Journal:  Front Pediatr       Date:  2016-03-31       Impact factor: 3.418

8.  Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: no.

Authors:  B Taylor Thompson; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2016-02-16       Impact factor: 17.440

9.  Immunoproteasome dysfunction augments alternative polarization of alveolar macrophages.

Authors:  S Chen; I E Kammerl; O Vosyka; T Baumann; Y Yu; Y Wu; M Irmler; H S Overkleeft; J Beckers; O Eickelberg; S Meiners; T Stoeger
Journal:  Cell Death Differ       Date:  2016-03-18       Impact factor: 15.828

10.  Oseltamivir and baloxavir: Dual treatment for rapidly developing ARDS on a patient with renal disease.

Authors:  Pool Tobar Vega; Elena Caldeira; Hasan Abad; Peguy Saad; Erik Lachance
Journal:  IDCases       Date:  2020-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.